PDCD1 and renal cell carcinoma: On December 14, 2023, the FDA approved belzutifan (Welireg, Merck & Co. Inc.)for patients with advanced RCC, following a PD-1 or PD-L1 checkpoint inhibitor and a VEGF-TKI based on the findings of LITESPARK 005 trial (52).